Frontiers in Medicine (Sep 2022)
Host-directed therapies in pulmonary tuberculosis: Updates on anti-inflammatory drugs
- Juan M. Cubillos-Angulo,
- Juan M. Cubillos-Angulo,
- Juan M. Cubillos-Angulo,
- Betânia M. F. Nogueira,
- Betânia M. F. Nogueira,
- María B. Arriaga,
- María B. Arriaga,
- María B. Arriaga,
- Beatriz Barreto-Duarte,
- Beatriz Barreto-Duarte,
- Beatriz Barreto-Duarte,
- Beatriz Barreto-Duarte,
- Mariana Araújo-Pereira,
- Mariana Araújo-Pereira,
- Mariana Araújo-Pereira,
- Catarina D. Fernandes,
- Caian L. Vinhaes,
- Caian L. Vinhaes,
- Caian L. Vinhaes,
- Klauss Villalva-Serra,
- Klauss Villalva-Serra,
- Klauss Villalva-Serra,
- Klauss Villalva-Serra,
- Vanessa M. Nunes,
- João P. Miguez-Pinto,
- Eduardo P. Amaral,
- Bruno B. Andrade,
- Bruno B. Andrade,
- Bruno B. Andrade,
- Bruno B. Andrade,
- Bruno B. Andrade
Affiliations
- Juan M. Cubillos-Angulo
- Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil
- Juan M. Cubillos-Angulo
- Faculdade de Medicina, Universidade Federal da Bahia, Salvador, BA, Brazil
- Juan M. Cubillos-Angulo
- Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative, Salvador, Brazil
- Betânia M. F. Nogueira
- Faculdade de Medicina, Universidade Federal da Bahia, Salvador, BA, Brazil
- Betânia M. F. Nogueira
- Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative, Salvador, Brazil
- María B. Arriaga
- Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil
- María B. Arriaga
- Faculdade de Medicina, Universidade Federal da Bahia, Salvador, BA, Brazil
- María B. Arriaga
- Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative, Salvador, Brazil
- Beatriz Barreto-Duarte
- Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil
- Beatriz Barreto-Duarte
- Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative, Salvador, Brazil
- Beatriz Barreto-Duarte
- Curso de Medicina, Universidade Salvador, Salvador, Brazil
- Beatriz Barreto-Duarte
- Programa de Pós-Graduação em Clínica Médica, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
- Mariana Araújo-Pereira
- Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil
- Mariana Araújo-Pereira
- Faculdade de Medicina, Universidade Federal da Bahia, Salvador, BA, Brazil
- Mariana Araújo-Pereira
- Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative, Salvador, Brazil
- Catarina D. Fernandes
- Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative, Salvador, Brazil
- Caian L. Vinhaes
- Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil
- Caian L. Vinhaes
- Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative, Salvador, Brazil
- Caian L. Vinhaes
- Bahiana School of Medicine and Public Health, Bahia Foundation for the Development of Sciences, Salvador, Brazil
- Klauss Villalva-Serra
- Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil
- Klauss Villalva-Serra
- Faculdade de Medicina, Universidade Federal da Bahia, Salvador, BA, Brazil
- Klauss Villalva-Serra
- Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative, Salvador, Brazil
- Klauss Villalva-Serra
- Curso de Medicina, Universidade Salvador, Salvador, Brazil
- Vanessa M. Nunes
- Curso de Medicina, Universidade Salvador, Salvador, Brazil
- João P. Miguez-Pinto
- Curso de Medicina, Universidade Salvador, Salvador, Brazil
- Eduardo P. Amaral
- Immunobiology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
- Bruno B. Andrade
- Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil
- Bruno B. Andrade
- Faculdade de Medicina, Universidade Federal da Bahia, Salvador, BA, Brazil
- Bruno B. Andrade
- Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative, Salvador, Brazil
- Bruno B. Andrade
- Programa de Pós-Graduação em Clínica Médica, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
- Bruno B. Andrade
- Bahiana School of Medicine and Public Health, Bahia Foundation for the Development of Sciences, Salvador, Brazil
- DOI
- https://doi.org/10.3389/fmed.2022.970408
- Journal volume & issue
-
Vol. 9
Abstract
Tuberculosis (TB) is a lethal disease and remains one of the top ten causes of mortality by an infectious disease worldwide. It can also result in significant morbidity related to persistent inflammation and tissue damage. Pulmonary TB treatment depends on the prolonged use of multiple drugs ranging from 6 months for drug-susceptible TB to 6–20 months in cases of multi-drug resistant disease, with limited patient tolerance resulting from side effects. Treatment success rates remain low and thus represent a barrier to TB control. Adjunct host-directed therapy (HDT) is an emerging strategy in TB treatment that aims to target the host immune response to Mycobacterium tuberculosis in addition to antimycobacterial drugs. Combined multi-drug treatment with HDT could potentially result in more effective therapies by shortening treatment duration, improving cure success rates and reducing residual tissue damage. This review explores the rationale and challenges to the development and implementation of HDTs through a succinct report of the medications that have completed or are currently being evaluated in ongoing clinical trials.
Keywords
